In:
British Journal of Clinical Pharmacology, Wiley, Vol. 80, No. 5 ( 2015-11), p. 1086-1096
Abstract:
Mycophenolic acid (MPA) suppresses lymphocyte proliferation through inosine monophosphate dehydrogenase (IMPDH) inhibition. Two formulations have been approved: mycophenolate mofetil (MMF) and enteric‐coated mycophenolate sodium (EC‐MPS). Pantoprazole (PAN) inhibits gastric acid secretion, which may alter MPA exposure. Data from healthy volunteers suggest a significant drug–drug interaction (DDA) between pantoprazole and MPA. In transplant patients, a decreased MPA area under the concentration–time curve (AUC) may lead to higher IMPDH activity, which may lead to higher acute rejection risk. Therefore this DDA was evaluated in renal transplant patients under maintenance immunosuppressive therapy. Methods In this single‐centre, open, randomized, four‐sequence, four‐treatment crossover study, the influence of PAN 40 mg on MPA pharmacokinetics such as (dose‐adjusted) AUC 0–12 h (dAUC) was analysed in 20 renal transplant patients ( 〉 6 months post‐transplantation) receiving MMF (1–2 g day –1 ) and EC‐MPS in combination with ciclosporin. The major metabolite MPA glucuronide (MPAG) and the IMPDH activity were also examined. Results MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml –1 mg –1 [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC‐MPS + PAN [dAUC: 46.30 ng h ml –1 mg –1 (95% CI 37.11, 55.49)]. Differences in dAUC and dose‐adjusted maximum concentration (dCmax) were not significant. Only for MMF [dAUC: 41.46 ng h ml –1 mg –1 (95% CI 32.38, 50.54)] and EC‐MPS [dAUC: 43.39 ng h ml –1 mg –1 (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)] . Simultaneous EC‐MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min–max: 0.5–10.0)] than EC‐MPS intake alone [3 h (1.5–12.0); P = 0.037]. Tmax was not affected for MMF [1.0 h (0.5–5.0)] ± pantoprazole [1.0 h (0.5–6.0), P = 0.928). No impact on MPAG pharmacokinetics or IMPDH activity was found. Conclusion Pantoprazole influences EC‐MPS and MMF pharmacokinetics but as it had no impact on MPA pharmacodynamics, the immunosuppressive effect of the drug was not impaired.
Type of Medium:
Online Resource
ISSN:
0306-5251
,
1365-2125
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1498142-7
SSG:
15,3
